Ashley Gallagher is an editor at Pharmacy Times®. She graduated from St. Bonaventure University in 2020 in journalism and mass communications. Previously, she worked as a pharmacy technician for a retail chain.
Study: African Ancestry Associated With Aggressive Breast Cancer Subtypes
September 6th 2023African ancestry was associated with higher odds of estrogen receptor-negative and triple-negative breast cancer; however, social environments were strongly associated with the survival of Black individuals with breast cancer.
Read More
Study: Blood Cancer Treatment Found to Kill Latent HIV-Infected Cells, Possible New Treatment
September 6th 2023Although antiretroviral therapies are the standard of care treatment for those with HIV, the drugs cannot target latent infections; however, venetoclax, a blood cancer treatment, shows promise.
Read More
COVID-19 Vaccination Reduces Serious Disease, But Lymphoma Patients Continue to Be Vulnerable
August 31st 2023Patients with lymphoma can be immunocompromised due to their disease, anti-cancer therapy, and concomitant immunosuppressive treatments, which make them more vulnerable to developing a COVID-19 infection.
Read More
Supplemental Biologics License Application Submitted to Expand Approval of Rybrevant for NSCLC
August 29th 2023The supplemental biologics license application for amivantamab-vmjw (Rybrevant) is supported by data from the phase 3 PAPILLON trial, evaluating the efficacy and safety of the drug in combination with chemotherapy for those with non–small cell lung cancer.
Read More
Study: Some Health Care Professionals Found to Spread COVID-19 Misinformation Via Social Media
August 25th 2023Investigators determined that there needs to be an evaluation of harm caused by pharmacy professionals who are in unique positions on social media, propagating misinformation about COVID-19, vaccines, treatment, masks, and other conspiracy theories.
Read More
Study: Multilevel Data Model Helps Estimate Likelihood of Delays in Cancer Treatment
August 24th 2023In the study, investigators incorporated data from electronic health records and social determinants of health into the model to determine the likelihood in delays when starting cancer therapy.
Read More
FDA Approves Hepzato Kit for Liver-Directed Treatment of Metastatic Uveal Melanoma
August 16th 2023Melphalan/hepatic delivery system (Hepzato Kit; Delcath Systems Inc) is currently the only liver-directed therapy approved by the FDA for the treatment of netastatic uveal melanoma and percutaneous hepatic perfusion.
Read More